U.S. markets closed

Stevanato Group S.p.A. (STVN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
28.70+0.07 (+0.24%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close28.63
Open28.63
Bid28.49 x 3100
Ask28.94 x 1000
Day's Range28.09 - 29.18
52 Week Range16.61 - 29.18
Volume352,004
Avg. Volume1,065,966
Market Cap8.462B
Beta (5Y Monthly)N/A
PE Ratio (TTM)49.23
EPS (TTM)0.58
Earnings DateAug 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.34
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-40% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Stevanato Group S.p.A.
    WST: Lowering target price to $470.00WEST PHARMACEUTICAL SERVICES has an Investment Rating of HOLD; a target price of $470.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Reuters

    Vaccine vial maker Stevanato to fund new plants, M&A with IPO money -chairman

    Italian vaccine vials maker Stevanato Group will use funds raised from its recent listing on the New York Stock Exchange to increase production capacity and for selected acquisitions, its executive chairman told Reuters on Thursday. According to its own estimates, it provides vials to about 90% of currently marketed COVID-19 vaccine programs. The medical packaging company raised $453.5 million in its July IPO and aims to build two new plants, which will focus on its high-margin products, including a drug containment solution called EZ-Fill.

  • Business Wire

    Stevanato Group Announces Second Quarter 2021 Financial Results

    PIOMBINO DESE, Italy, August 19, 2021--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter 2021 and established full-year 2021 guidance.

  • Business Wire

    Stevanato Group to Report Second Quarter Financial Results on August 19

    PIOMBINO DESE, Italy, August 11, 2021--Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the second quarter of fiscal year 2021 on Thursday, August 19, 2021.